MedTrace Logo

A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

NCT07446491 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-03-03

No results posted yet for this study

Summary

The main aim of this clinical trial is to assess the safety and efficacy of a single dose of PN20 in treatment of thrombocytopenia in adult patients with chronic liver disease undergoing an elective procedure. The main questions it aims to answer are:

* How effective is PN20 in treating thrombocytopenia in patients with chronic liver disease?
* Is PN20 safe in these patients? Participants will
* Receive a single subcutaneous injections of PN20 or placebo according to weight before an elective procedure,
* Visit the clinic for assessment.

Conditions

  • Thrombocytopenia Associated With Chronic Liver Disease

Interventions

DRUG

PN20

subcutaneous injection

DRUG

Placebo

subcutaneous injection

Sponsors & Collaborators

  • Chongqing Peg-Bio Biopharm Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-06
Primary Completion
2026-05-30
Completion
2026-06-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07446491 on ClinicalTrials.gov